PEPGEN INC. Operating Income
PEPGEN INC. (PEPG) reported Operating Income of -$18.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- PEPGEN INC. operating income (loss) for the quarter ending 2026-06-30 was -$18.94M.
- PEPGEN INC. operating income (loss) for the quarter ending 2026-03-31 was -$18.94M.
- PEPGEN INC. operating income (loss) for the quarter ending 2025-12-31 was -$19.70M.
- PEPGEN INC. operating income (loss) for the quarter ending 2025-09-30 was -$18.65M.
- PEPGEN INC. operating income (loss) for fiscal 2025 was -$93.61M.
- PEPGEN INC. operating income (loss) for fiscal 2024 was -$97.74M.
- PEPGEN INC. operating income (loss) for fiscal 2023 was -$84.77M.
- PEPGEN INC. operating income (loss) for fiscal 2022 was -$68.30M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$18.94M 10-Q · filed 2026-08-06 | -$37.88M 10-Q · filed 2026-08-06 | -$57.59M derived: sum of 3 quarters · filed 2026-08-06 | -$76.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$18.94M 10-Q · filed 2026-05-12 | -$38.65M derived: sum of 2 quarters · filed 2026-05-12 | -$57.30M derived: sum of 3 quarters · filed 2026-05-12 | -$81.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$19.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$38.36M derived: sum of 2 quarters · filed 2026-03-04 | -$62.29M derived: sum of 3 quarters · filed 2026-08-06 | -$93.61M 10-K · filed 2026-03-04 |
| 2025-09-30 | -$18.65M 10-Q · filed 2025-11-12 | -$42.59M derived: sum of 2 quarters · filed 2026-08-06 | -$73.91M 10-Q · filed 2025-11-12 | -$98.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$23.93M 10-Q · filed 2026-08-06 | -$55.25M 10-Q · filed 2026-08-06 | -$79.60M derived: sum of 3 quarters · filed 2026-08-06 | -$102.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$31.32M 10-Q · filed 2026-05-12 | -$55.67M derived: sum of 2 quarters · filed 2026-05-12 | -$78.84M derived: sum of 3 quarters · filed 2026-05-12 | -$109.26M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$24.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$47.52M derived: sum of 2 quarters · filed 2026-03-04 | -$77.94M derived: sum of 3 quarters · filed 2026-03-04 | -$97.74M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$23.17M 10-Q · filed 2025-11-12 | -$53.60M derived: sum of 2 quarters · filed 2025-11-12 | -$73.39M 10-Q · filed 2025-11-12 | -$94.20M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$30.43M 10-Q · filed 2025-08-07 | -$50.22M 10-Q · filed 2025-08-07 | -$71.03M derived: sum of 3 quarters · filed 2025-08-07 | -$95.81M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$19.80M 10-Q · filed 2025-05-08 | -$40.61M derived: sum of 2 quarters · filed 2025-05-08 | -$65.39M derived: sum of 3 quarters · filed 2025-05-08 | -$86.53M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$20.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$45.59M derived: sum of 2 quarters · filed 2025-02-24 | -$66.73M derived: sum of 3 quarters · filed 2025-02-24 | -$84.77M 10-K · filed 2025-02-24 |
| 2023-09-30 | -$24.78M 10-Q · filed 2024-11-07 | -$45.92M derived: sum of 2 quarters · filed 2024-11-07 | -$63.95M 10-Q · filed 2024-11-07 | -$81.17M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$21.14M 10-Q · filed 2024-08-08 | -$39.17M 10-Q · filed 2024-08-08 | -$56.39M derived: sum of 3 quarters · filed 2024-08-08 | -$75.94M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$18.03M 10-Q · filed 2024-05-14 | -$35.24M derived: sum of 2 quarters · filed 2024-05-14 | -$54.80M derived: sum of 3 quarters · filed 2024-05-14 | -$72.44M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$17.21M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-29 | -$36.77M derived: sum of 2 quarters · filed 2024-03-29 | -$54.41M derived: sum of 3 quarters · filed 2024-03-29 | -$68.30M 10-K/A · filed 2024-03-29 |
| 2022-09-30 | -$19.55M 10-Q · filed 2023-11-08 | -$37.20M derived: sum of 2 quarters · filed 2023-11-08 | -$51.09M 10-Q · filed 2023-11-08 | -$58.30M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$17.64M 10-Q · filed 2023-08-08 | -$31.53M 10-Q · filed 2023-08-08 | -$38.74M derived: sum of 3 quarters · filed 2023-08-08 | -$46.82M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$13.89M 10-Q · filed 2023-05-11 | -$21.10M derived: sum of 2 quarters · filed 2023-05-11 | -$29.18M derived: sum of 3 quarters · filed 2023-05-11 | -$34.37M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$7.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$15.29M derived: sum of 2 quarters · filed 2023-03-23 | -$20.48M derived: sum of 3 quarters · filed 2023-03-23 | -$27.11M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$8.08M 10-Q · filed 2022-11-10 | -$13.27M derived: sum of 2 quarters · filed 2022-11-10 | -$19.90M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$5.19M 10-Q · filed 2022-08-12 | -$11.82M 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | -$6.63M 10-Q · filed 2022-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |